home
portfolio
approach
team
careers
news
contact
investor portal
home
portfolio
approach
team
careers
news
contact
investor portal
Nextech Invest
MacroGenics Presents Updated Data from Phase 1 Study of Margetuximab at ASCO Annual Meeting 2015
MacroGenics Presents Updated Data from Phase 1 Study of Margetuximab at ASCO Annual Meeting 2015
Post navigation
Previous Post
Previous
TRACON’s TRC105 Receives FDA Fast Track Designation
Next Post
Next
Blueprint Medicines Debuts Preclinical Data for First-in-Class RET Drug Candidate